2025
Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring
Jiao H, Lin S, Gu J, Jiang D, Cui P, Huang Z, Fang Y, Wang H, Lin M, Tang H, Jiang T, Lin G, Zhang S, Yin H, Liang F, Wang J, Fan X, Qiu F, Yang Y, Li Z, Li B, Xiang J, Leng X, Han Y, Li C, Ai L, Hou Y, Wang G, Zhang Z, Cai S, Liu T, Yin J, Tan L. Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring. Molecular Cancer 2025, 24: 143. PMID: 40375301, PMCID: PMC12079821, DOI: 10.1186/s12943-025-02332-8.Peer-Reviewed Original ResearchConceptsCirculating tumor DNAOesophageal squamous cell carcinomaPathological complete responseResectable oesophageal squamous cell carcinomaPathologic complete response rateR0 resection ratePhase 2 studySquamous cell carcinomaNivolumab groupResection rateCell carcinomaLocally Advanced Squamous Cell CarcinomaTreating oesophageal squamous cell carcinomaTwo-year overall survival ratesCirculating tumor DNA dynamicsMulticenter phase 2 studyMulticentre phase 2 studyAdvanced squamous cell carcinomaCirculating tumor DNA levelsEvent-free survival rateMedian follow-up durationEffect of adjuvant therapyLong-term survival dataMonitoring minimal residual diseaseIntention-to-treat populationA multi-center study of symptoms in patients with esophageal cancer postoperatively: A networking analysis
Chen F, Shen Z, Xiong Y, Jiang Y, Zhou D, Guo J, Huang H, Knobf M, Ye Z. A multi-center study of symptoms in patients with esophageal cancer postoperatively: A networking analysis. European Journal Of Oncology Nursing 2025, 74: 102784. PMID: 39813978, DOI: 10.1016/j.ejon.2025.102784.Peer-Reviewed Original ResearchConceptsEsophageal cancerSymptom clustersDry mouthEating difficultiesCross-sectional surveyStudy of symptomsExploratory factor analysisSymptom burdenMulti-center studyBridge symptomsWeeks post-surgeryAcid indigestionPost-surgerySentinel symptomPatientsCancerMultiple centersSymptomsFactor analysisHeartburnCore symptomsBileWeeksCluster levelMouth
2024
Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial
Wu J, Zhang S, Yu S, An G, Wang Y, Yu Y, Liang L, Wang Y, Xu X, Xiong Y, Shao D, Shi Z, Li N, Wang J, Jin D, Liu T, Cui Y. Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial. Nature Communications 2024, 15: 8876. PMID: 39406730, PMCID: PMC11480398, DOI: 10.1038/s41467-024-53109-4.Peer-Reviewed Original ResearchConceptsEsophageal squamous cell carcinomaAdvanced gastric adenocarcinomaSquamous cell carcinomaTyrosine kinase inhibitorsGastric adenocarcinomaVariant allele frequencyAnlotinib hydrochlorideCell carcinomaVascular endothelial growth factor inhibitorsAnti-PD-1 antibodySafety of nivolumabAnti-PD-1Disease control rateMedian overall survivalProgression-free survivalGrowth factor inhibitorsPhase II trialOverall response rateOASIS trialPD-1Second-lineOverall survivalImmune signaturesII trialFactor inhibitorsState-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
Balmaceda N, Petrillo A, Krishnan M, Zhao J, Kim S, Klute K, Sundar R. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society Of Clinical Oncology Educational Book 2024, 44: e431060. PMID: 38771996, DOI: 10.1200/edbk_431060.Peer-Reviewed Original ResearchConceptsGastroesophageal cancerIntegration of immune checkpoint inhibitorsChimeric antigen receptor T cellsImmune checkpoint inhibitorsMetastatic gastroesophageal cancerPD-1 inhibitorsAdoptive cell therapyImmunotherapy-based approachesResectable gastroesophageal cancerAntibody-drug conjugatesCheckpoint inhibitorsPD-1Perioperative chemotherapyTargeted therapyT cellsTreatment paradigmFGFR2 inhibitorsCell therapyClinical challengeBispecific antibodiesImprove outcomesCancer treatmentReduced toxicityTherapyInhibitorsInconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer
Sundar R, Smyth E. Inconsistencies in the predictive value of PD-L1 in metastatic gastroesophageal cancer. The Lancet Gastroenterology & Hepatology 2024, 9: 495-497. PMID: 38492581, DOI: 10.1016/s2468-1253(24)00043-8.Commentaries, Editorials and Letters
2023
WATS3D: An Interobserver Study of Barrett's Esophagus–Associated Dysplasia Among Gastrointestinal Pathologists
Patil D, Goldblum J, Lauwers G, Lewis J, Robert M, Singer M, Odze R. WATS3D: An Interobserver Study of Barrett's Esophagus–Associated Dysplasia Among Gastrointestinal Pathologists. Clinical And Translational Gastroenterology 2023, 15: e00661. PMID: 38088399, PMCID: PMC10887448, DOI: 10.14309/ctg.0000000000000661.Peer-Reviewed Original ResearchMeSH KeywordsBarrett EsophagusEsophageal NeoplasmsHumansHyperplasiaPathologistsPrecancerous ConditionsReproducibility of ResultsConceptsBarrett's esophagusGI pathologistsCell blocksWide-area transepithelial samplingDetection rate of dysplasiaBE-associated dysplasiaRate of dysplasiaKappa valuesDetection of neoplasiaGastrointestinal (GILiquid cytologyEvaluate digital imagesSmear specimensGastrointestinal pathologistsInterobserver variabilityIndividual diagnostic categoriesStudy pathologistsInterobserver studyDysplasiaPathologistsCellular fociComputer-assisted analysisDiagnostic categoriesDetection rateTraining sessionsModifiable risk factors for esophageal cancer in endoscopic screening population: A modeling study
Zhang Q, Wang F, Feng H, Xing J, Zhu S, Zhang H, Li Y, Wei W, Zhang S. Modifiable risk factors for esophageal cancer in endoscopic screening population: A modeling study. Chinese Medical Journal 2023, 137: 350-352. PMID: 38030561, PMCID: PMC10836889, DOI: 10.1097/cm9.0000000000002878.Peer-Reviewed Original ResearchUltra-processed foods, adiposity and risk of head and neck cancer and oesophageal adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition study: a mediation analysis
Morales-Berstein F, Biessy C, Viallon V, Goncalves-Soares A, Casagrande C, Hémon B, Kliemann N, Cairat M, Blanco Lopez J, Al Nahas A, Chang K, Vamos E, Rauber F, Bertazzi Levy R, Barbosa Cunha D, Jakszyn P, Ferrari P, Vineis P, Masala G, Catalano A, Sonestedt E, Borné Y, Katzke V, Bajracharya R, Agnoli C, Guevara M, Heath A, Radoï L, Mancini F, Weiderpass E, Huerta J, Sánchez M, Tjønneland A, Kyrø C, Schulze M, Skeie G, Lukic M, Braaten T, Gunter M, Millett C, Agudo A, Brennan P, Borges M, Richmond R, Richardson T, Davey Smith G, Relton C, Huybrechts I. Ultra-processed foods, adiposity and risk of head and neck cancer and oesophageal adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition study: a mediation analysis. European Journal Of Nutrition 2023, 63: 377-396. PMID: 37989797, PMCID: PMC10899298, DOI: 10.1007/s00394-023-03270-1.Peer-Reviewed Original ResearchConceptsConsumption of ultra-processed foodsUltra-processed foodsWaist-to-hip ratioRisk of head and neck cancerUltra-processed food consumptionOesophageal adenocarcinoma riskEuropean Prospective InvestigationBody mass indexHead and neck cancerIncreased risk of HNCHigher consumption of ultra-processed foodsHead and neck cancer riskProspective InvestigationCancer and NutritionNegative control analysesOesophageal adenocarcinomaWaist-to-hipNegative control outcomesAssociated with greater riskMediation analysisNeck cancerAccidental deathEPIC participantsMass indexGreater riskAdvancing surveillance protocols for dysplastic Barrett’s esophagus after complete remission of intestinal metaplasia: Time to rethink biopsy strategy?
Burton S, Muniraj T. Advancing surveillance protocols for dysplastic Barrett’s esophagus after complete remission of intestinal metaplasia: Time to rethink biopsy strategy? Gastrointestinal Endoscopy 2023, 98: 733-734. PMID: 37863568, DOI: 10.1016/j.gie.2023.07.051.Peer-Reviewed Original ResearchAnti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors
Kim T, Bedard P, LoRusso P, Gordon M, Bendell J, Oh D, Ahn M, Garralda E, D’Angelo S, Desai J, Hodi F, Wainberg Z, Delord J, Cassier P, Cervantes A, Gil-Martin M, Wu B, Patil N, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho B. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors. JAMA Oncology 2023, 9: 1574-1582. PMID: 37768658, PMCID: PMC10540058, DOI: 10.1001/jamaoncol.2023.3867.Peer-Reviewed Original ResearchConceptsObjective response rateAdvanced solid tumorsAdverse eventsPhase 1bAntitumor activityCancer cohortNon-small cell lung cancer (NSCLC) cohortFrequent treatment-related adverse eventsInvestigator-assessed objective response rateSolid tumorsCell lung cancer cohortTreatment-related adverse eventsMajority of AEsEnd pointClinical cutoff dateDose-escalation cohortsDose-expansion cohortsEsophageal cancer cohortPhase 2 dosePrior cancer therapyPrimary end pointSecondary end pointsHalf of patientsNew safety signalsAntitumor immune responseCombining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer
Smyth E, Sundar R. Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer. The Lancet 2023, 402: 2168-2170. PMID: 37871605, DOI: 10.1016/s0140-6736(23)02296-1.Commentaries, Editorials and LettersEvidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply
Zhao J, Pietrantonio F, Sundar R. Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply. JAMA Oncology 2023, 9: 1005-1006. PMID: 37166787, DOI: 10.1001/jamaoncol.2023.0975.Commentaries, Editorials and LettersAnastomotic Stricture After Minimally Invasive Esophagectomy
Feingold P, Bryan D, Kuckelman J, Kennedy-Shaffer L, Wang V, Deeb A, Wee J, Jaklitsch M, Marshall M. Anastomotic Stricture After Minimally Invasive Esophagectomy. The Annals Of Thoracic Surgery 2023, 116: 712-719. PMID: 37244601, DOI: 10.1016/j.athoracsur.2023.05.013.Peer-Reviewed Original ResearchConceptsMinimally Invasive EsophagectomyInvasive esophagectomyAnastomotic strictureMinimally invasive esophagectomy approachesUnivariate analysis of patientsSingle-institution retrospective reviewAssociated with strictureAnalysis of patientsProportion of patientsDay of surgeryPercentage of patientsAssociated with anastomotic strictureTumor histologyTumor stageAnastomotic dilatationInitial dilationSurgeon variablesUnivariate analysisMultivariate analysisPrimary outcomeEsophagectomyStricturePatientsRisk factorsImprove outcomesPaclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
Stockton S, Catalano P, Cohen S, Burtness B, Mitchell E, Dotan E, Lubner S, Kumar P, Mulcahy M, Fisher G, Crandall T, Benson A. Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. The Oncologist 2023, 28: 827-e822. PMID: 37104870, PMCID: PMC10485278, DOI: 10.1093/oncolo/oyad096.Peer-Reviewed Original ResearchConceptsProgression-free survivalSecond-line therapyGastroesophageal junction cancerArm AMetastatic esophagealJunction cancerArm BMedian progression-free survivalRandomized phase II trialMedian overall survivalObjective response rateSecond-line treatmentAdvanced esophageal cancerInsulin-like growth factor 1 receptorPhase II trialStandard of careGrowth factor 1 receptorFactor 1 receptorStable diseaseII trialMetastatic settingPrimary endpointOverall survivalPreclinical evidenceClinical outcomesEsophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Ajani J, D'Amico T, Bentrem D, Cooke D, Corvera C, Das P, Enzinger P, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter W, Ilson D, Jalal S, Keswani R, Kim S, Kleinberg L, Klempner S, Lacy J, Licciardi F, Ly Q, Matkowskyj K, McNamara M, Miller A, Mukherjee S, Mulcahy M, Outlaw D, Perry K, Pimiento J, Poultsides G, Reznik S, Roses R, Strong V, Su S, Wang H, Wiesner G, Willett C, Yakoub D, Yoon H, McMillian N, Pluchino L. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 393-422. PMID: 37015332, DOI: 10.6004/jnccn.2023.0019.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Squamous CellEsophageal NeoplasmsEsophagogastric JunctionHumansNeoplasms, Second PrimaryQuality of LifeConceptsEsophagogastric junction cancerSquamous cell carcinomaJunction cancerMetastatic diseaseSystemic therapyNCCN Clinical Practice GuidelinesEsophageal squamous cell carcinomaMajor global health problemBest supportive careManagement of recurrentMultidisciplinary team managementClinical practice guidelinesTreatment of patientsGlobal health problemMicrosatellite instability statusNCCN guidelinesPalliative managementSupportive careEsophagogastric junctionCell carcinomaLower esophagusEsophageal cancerHER2 statusTumor locationBiomarker testingMulti-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer
Fernandez A, Robbins C, Gaule P, Agostini-Vulaj D, Anders R, Bellizzi A, Chen W, Chen Z, Gopal P, Zhao L, Lisovsky M, Liu X, Shia J, Wang H, Yang Z, McCann L, Chan Y, Weidler J, Bates M, Zhang X, Rimm D. Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer. Modern Pathology 2023, 36: 100128. PMID: 36889057, PMCID: PMC10198879, DOI: 10.1016/j.modpat.2023.100128.Peer-Reviewed Original ResearchConceptsOverall percent agreementCut pointsReal-world settingHigher cut pointsCell death ligand 1Percent agreementGastroesophageal junction cancerPD-L1 immunohistochemistryDeath ligand 1Companion diagnostic testsMessenger RNA measurementsJunction cancerCancer casesImmunohistochemistry assaysIHC resultsDrug AdministrationPredictive valueScoring systemRange of assaysDiagnostic testsInstitutional studyRNA measurementsImmunohistochemistryPoor specificityPathologist's readingEffectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
Yap D, Leone A, Wong N, Zhao J, Tey J, Sundar R, Pietrantonio F. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma. JAMA Oncology 2023, 9: 215-224. PMID: 36480211, PMCID: PMC9857522, DOI: 10.1001/jamaoncol.2022.5816.Peer-Reviewed Original ResearchMeSH KeywordsB7-H1 AntigenEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaHumansImmune Checkpoint InhibitorsLung NeoplasmsConceptsAdvanced esophageal squamous cell carcinomaImmune checkpoint inhibitorsEsophageal squamous cell carcinomaSquamous cell carcinomaPD-L1 expressionKaplan-Meier curvesLow PD-L1 expressionFirst-line trialsProgression-free survivalDuration of responsePD-L1Overall survivalCell carcinomaRandomized clinical trialsPooled analysisClinical trialsCheckpoint inhibitorsTumor proportionEffect of immune checkpoint inhibitorsLow programmed death ligand 1Benefit of immune checkpoint inhibitorsHazard ratioSurvival dataFirst-line settingICI-based regimens
2022
The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment
Yang Z, Lin H, Wang Z, Rong L, Zhang X, Wang L, Qin J, Xue X, Li Y, Xue L. The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment. BMC Cancer 2022, 22: 1180. PMID: 36384463, PMCID: PMC9670431, DOI: 10.1186/s12885-022-10276-1.Peer-Reviewed Original ResearchMeSH KeywordsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyHumansMargins of ExcisionNeoadjuvant TherapyPrognosisConceptsEsophageal squamous cell carcinomaEsophageal squamous cell carcinoma patientsRoyal College of Pathologists criteriaRoyal College of PathologistsCRM statusCollege of American PathologistsResection marginsPrognostic factorsPrognostic significancePrognostic valueSquamous cell carcinoma patientsLong-term prognostic significanceCircumferential resection marginCell carcinoma patientsCollege of American Pathologists criteriaSquamous cell carcinomaLymph node metastasisMultivariate survival analysisLong-term survivalPN0 subgroupPN3 subgroupsNeoadjuvant therapyNeoadjuvant treatmentPT3 tumorsTumor distanceN-nitrosamines-mediated downregulation of LncRNA-UCA1 induces carcinogenesis of esophageal squamous by regulating the alternative splicing of FGFR2
Wang X, Sun M, Gao Z, Yin L, Pu Y, Zhu Y, Wang X, Liu R. N-nitrosamines-mediated downregulation of LncRNA-UCA1 induces carcinogenesis of esophageal squamous by regulating the alternative splicing of FGFR2. The Science Of The Total Environment 2022, 855: 158918. PMID: 36169023, DOI: 10.1016/j.scitotenv.2022.158918.Peer-Reviewed Original ResearchMeSH KeywordsAlternative SplicingCarcinogenesisCell Line, TumorCell MovementCell ProliferationDown-RegulationEpigenesis, GeneticEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGene Expression Regulation, NeoplasticHeterogeneous-Nuclear Ribonucleoprotein Group F-HHumansMicroRNAsNitrosaminesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, Fibroblast Growth Factor, Type 2RNA, Long NoncodingConceptsFibroblast growth factor receptor 2Alternative splicingEsophageal squamous cell carcinomaExact molecular mechanismsHet-1A cellsDownregulation of UCA1Epithelial-mesenchymal transitionPI3K-AKT axisFGFR2-IIIcMolecular mechanismsPI3K-AktF proteinUnknown mechanismESCC cellsESCC progressionSplicingN-nitrosamine exposureGrowth factor receptor 2Squamous cell carcinomaDigestive system tumorsRegulation levelESCC tissuesFactor receptor 2High incidence areaLncRNA UCA1In-hospital prognosis of malignancy-related pulmonary embolism: an analysis of the national inpatient sample 2016–2018
Park D, An S, Kashoor I, Ezegwu O, Gupta S. In-hospital prognosis of malignancy-related pulmonary embolism: an analysis of the national inpatient sample 2016–2018. Journal Of Thrombosis And Thrombolysis 2022, 54: 630-638. PMID: 35876942, DOI: 10.1007/s11239-022-02684-8.Peer-Reviewed Original ResearchMeSH KeywordsEsophageal NeoplasmsHospital MortalityHospitalsHumansInpatientsLung NeoplasmsPrognosisPulmonary EmbolismRetrospective StudiesRisk FactorsConceptsOdds of in-hospital mortalityIn-Hospital MortalityAssociated with higher oddsPulmonary embolismNational Inpatient SamplePropensity score matchingEsophageal cancerLung cancerHigher oddsInpatient SamplePrognosis of PEScore matchingDiagnosis of PEClinically relevant covariatesPrimary diagnosis of PEMalignant groupOvarian cancerRetrospective studyMalignancyPrimary diagnosisRelevant covariatesCancerOddsPatientsMortality
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply